The U.S. Food and Drug Administration (FDA) has granted the designation of orphan drug to oNKord, Glycostem Therapeutics‘ cell-based therapy for the treatment of multiple myeloma, the company announced in a press release. This designation is awarded to potential therapies that prevent, diagnose, or treat conditions that affect fewer than 200,000 people in the U.S. It…
The U.S. Food and Drug Administration (FDA) has expanded the use of Keytruda (pembrolizumab) as a second-line treatment for adults with relapsed or refractory classical Hodgkin’s lymphoma (cHL) for whom initial therapies did not work or stopped working. The regulatory agency also updated an indication for children and adolescents with cHL, who may now be prescribed Keytruda…
An investigator-initiated trial soon will evaluate Clinical Laserthermia Systems’ Tranberg Thermal therapy, a focal ablation therapy, for the treatment of prostate cancer patients who have up to medium-grade, localized tumors. The trial will take place at the Otto-von-Guericke-University Magdeburg, in Germany, through a collaboration between the medical center and the developing company. It is expected…
The first clinical trial resulting from a new Zenith Epigenetic collaboration with the National Cancer Institute (NCI) will soon test a combination of the investigational therapy ZEN-3694 plus the immune checkpoint inhibitors Opdivo (nivolumab) and Yervoy (ipilimumab) for the treatment of resistant ovarian cancer. The new partnership was developed to test ZEN-3694 across several cancer indications. For this upcoming…
Trodelvy (sacituzumab govitecan), compared with standard chemotherapy, significantly prolonged overall survival and improved the overall response rate of patients with metastatic triple-negative breast cancer (mTNBC) who had at least two prior lines of therapy, a Phase 3 trial reported. Based on these findings, recently presented as a late-breaking abstract at the European Society for Medical Oncology…
A recent collaboration between Cytovia Therapeutics and Inserm, the French National Institute of Health and Medical Research, aims to advance new immunotherapies against multiple myeloma based on natural killer cells. Cytovia is developing two distinct therapies for myeloma; one activates and brings these immune cells closer to the cancer cells, the other uses engineered natural killer…
A Phase 2/3 clinical trial is again recruiting participants to continue investigating the immunomodulator Leukine (sargramostim) in combination with checkpoint inhibitors Yervoy (ipilimumab) and Opdivo (nivolumab) as an initial treatment for patients with melanoma. The decision to resume enrollment follows positive — but as yet, undisclosed — safety and survival results from the first 250…
A new artificial intelligence (AI) algorithm has been developed that can accurately detect and grade prostate cancer, using slide images from patient core needle prostate biopsies, a study reports. The study, “An artificial intelligence algorithm for prostate cancer diagnosis in whole slide images of core needle biopsies: a blinded clinical validation and deployment study,” was…
The Ovarian Cancer Research Alliance (OCRA) has partnered with Microsoft‘s AI for Health initiative, with the ultimate goal of accelerating ovarian cancer research using data science and artificial intelligence (AI). AI is a broad term that encompasses any use of a computer to accomplish tasks, from sorting to making complex decisions, that are usually associated…
The National Cancer Institute (NCI) has awarded $1.7 million to support the work of a University of Arkansas for Medical Sciences (UAMS) researcher in developing a therapy that can preserve bone health, and prevent or delay cancer relapse in people with multiple myeloma. This form of blood cancer causes malignant cancer cells to accumulate in…
